Tilray | TRLY - Cost Of Sales


Tilray reported $164.37M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 8.22M 80.38M Mar/2026
Avita Medical AUD 3.3M 166K Dec/2025
Canopy Growth CAD 62.98M 9.91M Mar/2026
Cronos Group USD 24.94M 1.55M Jun/2026
Divis Laboratories Ltd INR 11.19B 1.2B Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
IQVIA Holdings USD 3.22B 141M Jun/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Moderna USD 93M 862M Jun/2026
Organigram Holdings CAD 43.39M 13.54M Mar/2026
Organon & Co USD 711M 34M Jun/2026
Revvity USD 312.82M 10.64M Jun/2026
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.3B 59.5M Jun/2026
Xeris Pharmaceuticals USD 10.57M 3.08M Mar/2026
Zealand Pharma A/S 410K 5K Jun/2025